DrPH: Indiana University, Fairbanks School of Public Health
MA: Marymount University
Sickle cell anemia; global health; public health; healthcare infrastructure and capacity building in resource-limited settings
Growth and puberty in African children with sickle cell anemia treated with hydroxyurea. Blood advances. 2026; 10(13):4483-4494.
Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea. Blood advances. 2026.
High early mortality among Ugandan children with sickle cell anemia and congenital HIV identified by newborn screening. Blood Glob Hematol. 2026; 2(2):100093.
Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial. Acta Haematologica. 2026; 1-11.
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Blood advances. 2026; 10(2):418-427.
Development of disease-specific growth curves from Kenyan children with sickle cell anemia. Blood Glob Hematol. 2025; 1(3):100031.
Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa. Blood. 2025; 146(Supplement 1):300-300.
Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening. Blood. 2025; 146(Supplement 1):2668.
Measles vaccine-induced sero-protection among children with sickle cell anemia. Blood. 2025; 146(Supplement 1):1168.
Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nature Medicine. 2025; 31(7):2204-2212.
Teresa S. Latham, DrPH, PhD, Luke R. Smart, MD3/1/2023